Company news

Anavex Life Sciences Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

April 25, 2022

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

April 6, 2022

Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit

March 27, 2022

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference

March 14, 2022

Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum

March 8, 2022

Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

March 3, 2022

Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results

February 8, 2022

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

February 3, 2022

Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022

February 2, 2022

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome

January 31, 2022

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71

January 9, 2022

Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer

January 5, 2022

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

January 4, 2022

Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference

December 13, 2021

Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 28, 2021

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results

November 23, 2021

Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021

November 16, 2021

Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease

November 9, 2021

Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference

October 14, 2021

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease

October 12, 2021

Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®

September 26, 2021

Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021

September 26, 2021

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 19, 2021

Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)

August 25, 2021

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

August 11, 2021

Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021

August 4, 2021

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

August 3, 2021

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease

July 28, 2021

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients wit...

June 27, 2021

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

June 23, 2021

Anavex Life Sciences Announces $50 Million Registered Direct Offering

June 21, 2021

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

June 20, 2021

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease

June 13, 2021

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease

June 7, 2021

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions

June 2, 2021

Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

May 25, 2021

Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook

May 12, 2021

Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit

May 6, 2021

Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021

May 5, 2021

Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development

May 4, 2021

Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference

April 25, 2021

Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome

April 11, 2021

Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference

April 7, 2021

Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021

April 6, 2021

Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”

March 15, 2021

Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

March 3, 2021

Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®

February 21, 2021

Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021

February 17, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.